Satyanarayan Chava

“We are pleased with the substantial programs company making across various business segments. We continue to report strong growth in CDA moordiness, steady momentum in affordable medicine portfolio because of our major advancement in our partners' clinical and commercial programs.”

“We continue to make steady progress and a strong demand environment for multiple complex technology platforms and integrated manufacturing capabilities.”

“Our company's purpose of chemistry for better living guides us everything what we do. In 2026, we significantly accelerated our performance reflecting sustained demand in technology-driven commercial offerings.”